Form 11-K ELI LILLY & Co For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- Oil gains 3% as US-Iran peace talks in stalemate
- October Fed meeting hinges on this key economic data, Citi says
- Trump says men arrested at UK air base used by US were looking to do 'big damage'
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
- Oppenheimer sees AI software winners as focus shifts to ROI
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Dollar near two-month high as US-Iran stalemate bolsters oil, Fed rate hike bets
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
June 23, 2025 12:14 PM EDTMorgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,133.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "One of the side effects of the dramatic weight loss of GLP-1 based medications is that people also lose muscle/lean body mass. LLY, REGN, BHVN and other companies are developing drugs targeting the activin receptor pathway with the goal of preventing/slowing muscle mass loss. LLY's program broadly blocks the receptors (and hence activins, myostatin, and GDF11 ligands simultaneously), while REGN is focused on selectively blocking two ligands (myostatin and activin A)... More
